Buy Ibrance (Palbociclib)
Price range: €1,275.00 through €1,599.00
What is Ibrance (palbociclib) for?
Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (hormone therapy) as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression after endocrine therapy.
How does Ibrance (palbociclib) work?
Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Before a cell can divide, it must go through four phases. The first phase is a growth phase (G1 phase), the second a synthesis phase (S phase), the third another growth phase (G2 phase), and the final phase, in which the cell divides (M phase). Cancer cells divide extremely rapidly and pass through these four phases quickly. Palbociclib blocks the transition from the first G1 phase to the second S phase. This occurs by inhibiting cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) – two proteins involved in entering the S phase [1] .
Is Ibrance (palbociclib) approved?
Palbociclib was approved by:
- Food and Drug Administration (FDA), USA:
- February 3, 2015, for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease
- On March 31, 2017, the accelerated approval was converted into a regular approval for use in combination with an aromatase inhibitor (a hormone therapy) as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression after endocrine therapy.
- On April 4, 2019, the marketing authorization was extended to include the indication for men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer when Ibrance (palbociclib) is used in combination with an aromatase inhibitor or fulvestrant.
- European Medical Agency (EMA), European Union, 11 November 2016
And
- Therapeutic Goods Administration (TGA), Australien, 3. Mai 2017
- Health Canada, June 5, 2018
- Medsafe, June 29, 2017
For use in combination with an aromatase inhibitor (e.g., letrozole) or with fulvestrant for the treatment of women with HR+/HER2- locally advanced or metastatic breast cancer who have previously received endocrine therapy.
How do I take Ibrance (palbociclib)?
The standard dose is:
-
125 mg daily for 21 consecutive days, followed by a 7-day treatment with 2.5 mg letrozole daily continuously during the 28-day cycle.
Detailed information on the dosage and administration of palbociclib can be found in the “Resources” section.
Ask your doctor for an individual dosage.
Common adverse reactions or side effects of Ibrance (palbociclib)
The most common side effects of palbociclib are:
- neutropenia
- Leukopenia
- fatigue
- anemia
- Infection
- Nausea
| Quantity |
21 tablets of 100 mg ,21 tablets of 75 mg ,21 tablets of 125 mg ,21 capsules of 75 mg ,21 capsules of 100 mg (Limited availability) ,21 capsules of 125 mg (Limited availability) |
|---|
Shipping and delivery
All orders will only be shipped after payment confirmation. Please enter your shipping details and select the payment method that suits you best.
Shipping costs:
You should always be clearly informed about the total price of your purchase, including delivery and any other associated costs.
You must explicitly agree to any additional charges, for example, if the retailer offers express shipping or gift wrapping.
Damaged Goods:
The retailer is responsible for all damage to the product, from shipping to receipt.
If you have purchased an item that does not match the advertised product in appearance or function, you have the right to request a repair, a replacement, or, if neither of these is possible, a refund.
- Non-delivery:
If you have not received the product within 30 days or by the agreed date, you must notify the seller and grant them a reasonable extension of the delivery period.
For example, if the seller informs you of a one-week delay due to problems with their suppliers, it seems reasonable to grant them this additional week. If, despite the extension, the seller still fails to fulfill their obligation to deliver, you have the right to withdraw from the contract and receive an immediate refund.
Related products
Buy Darzalex (Daratumumab)
Who is Darzalex (daratumumab) suitable for?
Darzalex (daratumumab) is indicated for patients with:-
Newly diagnosed multiple myeloma for which autologous stem cell transplantation is not an option (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.
-
Patients with multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone.
-
Patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (third-line therapy). For this indication, it is used in combination with pomalidomide and dexamethasone.
-
Multiple myeloma patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are doubly refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.
Buy Kadcyla (Trastuzumab Emtansine)
Buy Keytruda (Pembrolizumab)
Buy Opdivo (Nivolumab)
What is Opdivo (nivolumab) for?
Opdivo (nivolumab) is indicated for the treatment of patients with the following conditions:- metastatic melanoma as monotherapy or in combination with ipilimumab
- metastatic non-small cell lung cancer (NSCLC) whose cancer has progressed during or after chemotherapy
- advanced renal cell carcinoma who have previously received anti-angiogenic therapy
- classical Hodgkin lymphoma that has relapsed or progressed after other treatments
- Recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) with disease progression during or within 6 months of receiving platinum-based chemotherapy
- locally advanced, unresectable or metastatic urothelial carcinoma after progression under platinum-based therapy
- Metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) that has progressed after treatment with a fluoropyrimidine, oxaliplatin and irinotecan
- hepatocellular carcinoma in patients previously treated with sorafenib
- for the adjuvant treatment of completely resected esophageal cancer or cancer of the gastroesophageal junction (GEJ) with persistent pathological residual disease in patients who have received neoadjuvant radiochemotherapy (CRT).
Buy Perjeta (Pertuzumab)
What is Perjeta (pertuzumab) for?
Perjeta (pertuzumab) is indicated for the treatment of HER2-positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory or early breast cancer as part of a complete early breast cancer treatment regimen.
Buy Tecentriq (atezolizumab)
Reviews
There are no reviews yet.